India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient adherence remains fragile. Host and ET’s pharma editor Vikas Dandekar talks to Sheetal Sapale, Vice President, Pharmarack, Dr. Rajiv Kovil, Diabetologist, Saurabh Agarwal, Director at HAB Pharmaceuticals and Research, Dr. Saurabh Jain, Vice President - Global Delivery Centers, Indegene and Vijay Charlu, President of Domestic Business, Corona Remedies to dissect who survives the shakeout, what it means for a slew of weight loss drugs in India, whether it will revolutionise metabolic treatment and whether India is truly ready for its statin moment.
You can follow Vikas Dandekar on his social media: X and Linkedin and read her Newspaper Articles.
Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.
Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.
See omnystudio.com/listener for privacy information.
